Claire S. Philipp
Research Subjects
Claire S. Philipp has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Connie H. Miller
Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA
4 shared publications Ambarina Faiz
Division of Hematology, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ
3 shared publicationsA. Dilley
Center for Birth Defects, Centers for Disease Control and Prevention, Atlanta, GA
2 shared publicationsCharletta Ayers
2 shared publicationsG. Bachmann
Department of Obstetrics and Gynecology, UMDNJ‐Robert Wood Johnson Medical School, New Brunswick, NJ, USA
2 shared publicationsGloria Bachmann
2 shared publications
Latest Publications
- 1 March 2011
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 204 (3) , 209.e1-209.e7
Evaluation of a screening tool for bleeding disorders in a US multisite cohort of women with menorrhagia
- 1 March 2011
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 204 (3) , 209.e1-209.e7
Evaluation of a screening tool for bleeding disorders in a US multisite cohort of women with menorrhagia
- Open Access
- 4 December 2010
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2010 (1) , 191-196
The Aging Patient with Hemophilia: Complications, Comorbidities, and Management Issues
Improvements in hemophilia care and antiviral treatments have resulted in increases in median life expectancy for persons with congenital hemophilia A and B. Currently, 2% of hemophilia A and B patients surveyed in US comprehensive hemophilia treatment centers are 65 years of age or older and 15% are 45 years or older. Many of the complications of hemophilia, including intracranial hemorrhage, joint disease, and inhibitor development, increase with increasing age. Hepatocellular carcinoma and end-stage liver disease are increasing in the older hemophilia population due to infection with hepatitis C (HCV) and HCV/HIV coinfection. Older hemophilia patients also now face the same medical conditions associated with aging in the general population, including cardiovascular disease and cancer. Complex hemostatic management, sometimes in conjunction with antithrombotic management, with extensive cross-specialty clinical and laboratory coordination may be required for the care of the older hemophilia patient. Because elderly hemophilia patients currently represent a small portion of the overall hemophilia population, there is little in the way of clinical data to guide recommendations. Registry databases and cooperative group studies are needed for the development of evidence-based guidelines for the older hemophilia population, which is anticipated to expand in the future.
- 4 December 2010
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2010 (1) , 191-196
Open AccessThe Aging Patient with Hemophilia: Complications, Comorbidities, and Management Issues
Improvements in hemophilia care and antiviral treatments have resulted in increases in median life expectancy for persons with congenital hemophilia A and B. Currently, 2% of hemophilia A and B patients surveyed in US comprehensive hemophilia treatment centers are 65 years of age or older and 15% are 45 years or older. Many of the complications of hemophilia, including intracranial hemorrhage, joint disease, and inhibitor development, increase with increasing age. Hepatocellular carcinoma and end-stage liver disease are increasing in the older hemophilia population due to infection with hepatitis C (HCV) and HCV/HIV coinfection. Older hemophilia patients also now face the same medical conditions associated with aging in the general population, including cardiovascular disease and cancer. Complex hemostatic management, sometimes in conjunction with antithrombotic management, with extensive cross-specialty clinical and laboratory coordination may be required for the care of the older hemophilia patient. Because elderly hemophilia patients currently represent a small portion of the overall hemophilia population, there is little in the way of clinical data to guide recommendations. Registry databases and cooperative group studies are needed for the development of evidence-based guidelines for the older hemophilia population, which is anticipated to expand in the future.
- 1 December 2010
- Published by Elsevier in Journal of Pediatric and Adolescent Gynecology
- Vol. 23 (6) , S11-S14
Platelet Disorders in Adolescents
- 1 December 2010
- Published by Elsevier in Journal of Pediatric and Adolescent Gynecology
- Vol. 23 (6) , S11-S14
Platelet Disorders in Adolescents
- 1 February 2008
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 198 (2) , 163.e1-163.e8
Development of a screening tool for identifying women with menorrhagia for hemostatic evaluation
- 1 February 2008
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 198 (2) , 163.e1-163.e8
Development of a screening tool for identifying women with menorrhagia for hemostatic evaluation
- 26 August 2005
- Published by Wiley in Haemophilia
- Vol. 11 (5) , 497-503
Screening women with menorrhagia for underlying bleeding disorders: the utility of the platelet function analyser and bleeding time
Summary. Menorrhagia is a very common clinical problem among women of reproductive age and recent studies have suggested that underlying bleeding disorders, particularly von Willebrand's deficiency and platelet function defects, are prevalent in women presenting with menorrhagia. The objective of this study was to determine the utility of the platelet function analyser (PFA‐100) and bleeding time (BT) as initial screening tests for underlying bleeding disorders in women with menorrhagia. In this study, 81 women with a physician diagnosis of menorrhagia underwent PFA‐100 testing, BT and comprehensive haemostatic testing. The effectiveness of the PFA‐100 and BT as screening tools in women with menorrhagia was assessed using results of haemostatic testing for von Willebrand's disease (VWD) and platelet dysfunction. In women presenting with menorrhagia, the PFA‐100 had a sensitivity 80%, specificity 89%, positive predictive value (PPV) 33%, negative predictive value (NPV) 98% and efficiency 88% for VWD. For platelet aggregation defects, the PFA‐100 closure time had a sensitivity 23%, specificity 92%, PPV of 75%, NPV of 52% and efficiency 55%. The data suggest that the PFA‐100 may be useful in stratifying women with menorrhagia for further von Willebrand testing; however, neither the PFA‐100 nor the BT tests are effective for purposes of classifying women for standard platelet aggregometry testing in women presenting with menorrhagia.
- 26 August 2005
- Published by Wiley in Haemophilia
- Vol. 11 (5) , 497-503
Screening women with menorrhagia for underlying bleeding disorders: the utility of the platelet function analyser and bleeding time
Summary. Menorrhagia is a very common clinical problem among women of reproductive age and recent studies have suggested that underlying bleeding disorders, particularly von Willebrand's deficiency and platelet function defects, are prevalent in women presenting with menorrhagia. The objective of this study was to determine the utility of the platelet function analyser (PFA‐100) and bleeding time (BT) as initial screening tests for underlying bleeding disorders in women with menorrhagia. In this study, 81 women with a physician diagnosis of menorrhagia underwent PFA‐100 testing, BT and comprehensive haemostatic testing. The effectiveness of the PFA‐100 and BT as screening tools in women with menorrhagia was assessed using results of haemostatic testing for von Willebrand's disease (VWD) and platelet dysfunction. In women presenting with menorrhagia, the PFA‐100 had a sensitivity 80%, specificity 89%, positive predictive value (PPV) 33%, negative predictive value (NPV) 98% and efficiency 88% for VWD. For platelet aggregation defects, the PFA‐100 closure time had a sensitivity 23%, specificity 92%, PPV of 75%, NPV of 52% and efficiency 55%. The data suggest that the PFA‐100 may be useful in stratifying women with menorrhagia for further von Willebrand testing; however, neither the PFA‐100 nor the BT tests are effective for purposes of classifying women for standard platelet aggregometry testing in women presenting with menorrhagia.
- 1 January 2005
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 105 (1) , 61-66
Age and the Prevalence of Bleeding Disorders in Women With Menorrhagia
OBJECTIVE: A study was conducted to evaluate the frequency and types of hemostatic defects occurring in adolescent and perimenopausal-age women diagnosed with menorrhagia. METHODS: A total of 115 women with a physician diagnosis of menorrhagia, including 25 adolescent women, 25 perimenopausal-age women, and 65 women between the ages of 20 and 44, underwent comprehensive hemostatic testing for possible bleeding disorders. Frequencies of bleeding disorders were calculated and compared. RESULTS: Forty-seven percent of women were found to have hemostatic abnormalities, including platelet dysfunction, von Willebrand’s disease, and coagulation factor deficiencies. Adolescents and perimenopausal-age women with menorrhagia were just as likely to have hemostatic abnormalities as were women aged 20 to 44. CONCLUSION: These results demonstrate that underlying bleeding disorders are frequently found in adolescent, postadolescent reproductive age, and perimenopausal-age women presenting with menorrhagia and suggest that women with menorrhagia should be considered for further hemostatic evaluation. LEVEL OF EVIDENCE: II-2
- 1 January 2005
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 105 (1) , 61-66
Age and the Prevalence of Bleeding Disorders in Women With Menorrhagia
OBJECTIVE: A study was conducted to evaluate the frequency and types of hemostatic defects occurring in adolescent and perimenopausal-age women diagnosed with menorrhagia. METHODS: A total of 115 women with a physician diagnosis of menorrhagia, including 25 adolescent women, 25 perimenopausal-age women, and 65 women between the ages of 20 and 44, underwent comprehensive hemostatic testing for possible bleeding disorders. Frequencies of bleeding disorders were calculated and compared. RESULTS: Forty-seven percent of women were found to have hemostatic abnormalities, including platelet dysfunction, von Willebrand’s disease, and coagulation factor deficiencies. Adolescents and perimenopausal-age women with menorrhagia were just as likely to have hemostatic abnormalities as were women aged 20 to 44. CONCLUSION: These results demonstrate that underlying bleeding disorders are frequently found in adolescent, postadolescent reproductive age, and perimenopausal-age women presenting with menorrhagia and suggest that women with menorrhagia should be considered for further hemostatic evaluation. LEVEL OF EVIDENCE: II-2
- 1 March 2003
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 1 (3) , 477-484
Platelet functional defects in women with unexplained menorrhagia
- 1 March 2003
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 1 (3) , 477-484
Platelet functional defects in women with unexplained menorrhagia
- 1 November 1997
- Published by Elsevier in American Heart Journal
- Vol. 134 (5) , 978-984
Association of hemostatic factors with peripheral vascular disease
- 1 November 1997
- Published by Elsevier in American Heart Journal
- Vol. 134 (5) , 978-984
Association of hemostatic factors with peripheral vascular disease